Consulting

Premier Insight 271: Enrolling Sickle Cell Patients Is Tough – So We Got Busy

Kick off a study of a drug to treat sickle cell disease and you’re facing a tough climb. Experimental drugs for sickle cell are few and far between, so there is little in the way of clinical trial infrastructure. The patient population is demographically challenging, too, made up largely of socioeconomically disadvantaged people who find it difficult to comply with the rigors of clinical drug trials.